Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Tiraboschi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Neurology|June 9, 2004
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer diseaseP Tiraboschi, L A Hansen, E Masliah, et al.
Neurology|November 23, 2000
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's diseaseP Tiraboschi, L A Hansen, M Alford, et al.
Progress in Clinical and Biological Research|January 1, 1989
An example of a clinical trial in patients with Alzheimer's disease: some methodological issuesU Lucca, G Menasce, M Comelli, et al.
Journal of Clinical Pharmacology|September 1, 1993
Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteersS Caccia, S Confalonieri, G Guiso, et al.
Journal of Clinical Pharmacology|July 1, 1994
Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteersS Caccia, S Confalonieri, G Guiso, et al.
Journal of Neurointerventional Surgery|October 13, 2011
Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trialA Ciccone, L Valvassori, M Ponzio, et al.
Neurology|February 11, 2000
E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's diseaseJ Corey-Bloom, P Tiraboschi, L A Hansen, et al.
Neurology|November 1, 1991
Long-term acetyl-L-carnitine treatment in Alzheimer's diseaseA Spagnoli, U Lucca, G Menasce, et al.
Neurology|February 11, 2000
Cholinergic dysfunction in diseases with Lewy bodiesP Tiraboschi, L A Hansen, M Alford, et al.
Neurology|April 13, 2005
Smoking affects the phenotype of Alzheimer diseaseM N Sabbagh, S L Tyas, S C Emery, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Neurology|June 9, 2004
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer diseaseP Tiraboschi, L A Hansen, E Masliah, et al.
Neurology|November 23, 2000
The decline in synapses and cholinergic activity is asynchronous in Alzheimer's diseaseP Tiraboschi, L A Hansen, M Alford, et al.
Progress in Clinical and Biological Research|January 1, 1989
An example of a clinical trial in patients with Alzheimer's disease: some methodological issuesU Lucca, G Menasce, M Comelli, et al.
Journal of Clinical Pharmacology|September 1, 1993
Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteersS Caccia, S Confalonieri, G Guiso, et al.
Journal of Clinical Pharmacology|July 1, 1994
Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteersS Caccia, S Confalonieri, G Guiso, et al.
Journal of Neurointerventional Surgery|October 13, 2011
Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trialA Ciccone, L Valvassori, M Ponzio, et al.
Neurology|February 11, 2000
E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's diseaseJ Corey-Bloom, P Tiraboschi, L A Hansen, et al.
Neurology|November 1, 1991
Long-term acetyl-L-carnitine treatment in Alzheimer's diseaseA Spagnoli, U Lucca, G Menasce, et al.
Neurology|February 11, 2000
Cholinergic dysfunction in diseases with Lewy bodiesP Tiraboschi, L A Hansen, M Alford, et al.
Neurology|April 13, 2005
Smoking affects the phenotype of Alzheimer diseaseM N Sabbagh, S L Tyas, S C Emery, et al.
Pageof 3